- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers
- FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C
- FMC-376 has the potential to transform patient outcomes with its ability to overcome both innate and acquired resistance mechanisms and brain metastases
Feb. 22, 2024 -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-cau